Gilead: Twice-Yearly Lenacapavir Was Generally Well-Tolerated, With No Significant or New Safety Concerns Identified
吉利德:每年兩次的Lenacapavir總體上被很好地耐受,未發現任何重大或新的安全問題
Gilead: Twice-Yearly Lenacapavir Was Generally Well-Tolerated, With No Significant or New Safety Concerns Identified
吉利德:每年兩次的Lenacapavir總體上被很好地耐受,未發現任何重大或新的安全問題
譯文內容由第三人軟體翻譯。
使用瀏覽器的分享功能,分享給你的好友吧